On April 3, the FDA sent a letter to 16 drug companies asking them to stop using “misbranded” online advertising. In an article in PRWeek by Jaimy Lee, Fleishman-Hillard pharma specialist Mark Senak
discusses the reprimands and suggests that, when it comes to Internet advertising, the agency may not be “enunciating clear policy.”
Does FDA Create Confusion Regarding Communications?
Posted on April 8th, 2009 | More Digital & Social Media · Healthcare · Public Affairs
Related Posts
-
Will Social Media Stamp Out Email?
Is social media marketing responsible for the “impending demise” of email? The digital specialists from Fleishman DNA
examine the platform’s decline, including how the changes could affect brands. Posted on February 8th, 2012 | More B2C · Digital & Social Media · Mobile · Small Business Owners
-
Facebook 2.IPO: Why Communicators Should Watch
While Facebook prepares to go public, communicators appear to be in for a huge learning experience. In a PRWeek article, International Advisory Board member John Onoda weighs in — and suggests we’ll see “a new chapter of PR unfold.”
Posted on February 8th, 2012 | More Analysts & Investors · Digital & Social Media · Financial Communications
-
The Role of Digital Communications and ‘Pharmacovigilance’
In an article in PharmaVoice, pharma specialist Mark Senak
discusses pharmacovigilance communication and explains why the best digital strategy includes “the concept of a two-way exchange.”Posted on February 3rd, 2012 | More Crisis Communications · Digital & Social Media · Healthcare
